Persistent cutaneous phaeohyphomycosis caused by Brunneofusispora hyalina in a patient with a heterozygous CARD9 variant: the opportunistic potential of a newly described environmental fungus
7 affiliations
- 1Department of Medical Mycology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China
- 2Chinese Academy of Medical Sciences Collection Centre of Pathogen Microorganisms-D (CAMS-CCPM-D), Nanjing, China
- 3Department of Microbiology & Immunology, Georgetown University Medical Center, Washington, DC, United States
- 4Dermatology and Venereology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China
- 5State Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
- 6Department of Medical Microbiology, The People’s Hospital of Suzhou New District, Suzhou, China
- 7Institute of Plant Protection, Jiangsu Academy of Agricultural Sciences, Nanjing, China
Abstract
Objectives: This report documents the first isolation of rare dematiaceous fungus Brunneofusispora hyalina from a cutaneous lesion in a patient with heterozygous CARD9 variant. The study characterizes this novel pathogen and simulates infection and treatment processes to understand this opportunist and explore therapeutic strategies.
Methods: Direct microscopy and histopathology confirmed the fungal infection. By collecting morphological images of the isolate, assessing temperature-dependent growth, performing multi-locus and whole-genome sequencing, and conducting antifungal susceptibility testing, the new pathogen’s virulence and antifungal resistance were comprehensively analyzed. Using CARD9-deficient mice to establish infection models and administer drug treatments.
Results: The patient, confirmed by whole-exome sequencing to have a heterozygous CARD9 variant, was diagnosed with phaeohyphomycosis caused by B. hyalina through barcode sequencing. Meanwhile, functional annotation revealed metabolic versatility and enrichment in secondary metabolite pathways, while 395 PHI homologs were identified mainly from plant-pathogenic fungi. The strain exhibited abundant hyphal anastomosis and psychrotolerant growth. Antifungal susceptibility tests using modified agar dilution and broth dilution methods showed low MICs to voriconazole, posaconazole, itraconazole, and terbinafine, with values of 0.5-1 µg/mL, 0.5–2 µg/mL, 1–2 µg/mL, and 0.25–0.5 µg/mL, respectively. However, fluconazole showed a high MIC (128 µg/mL). In contrast, amphotericin B inhibitory concentrations differed substantially between two testing methods, with discrepancies exceeding three twofold dilution titers. In a CARD9 knockout mouse model, B. hyalina caused persistent inflammatory infections without mortality, whereas infection in wild-type mice had self-limiting symptoms. Despite six weeks of combined antifungal therapy, complete eradication of infection was not achieved.
Conclusions: B. hyalina is a new opportunistic fungus causing phaeohyphomycosis, particularly in individuals with CARD9 variants. Genomic analysis shows that B. hyalina shares many genes with plant pathogens and lacks specialized human virulence factors, suggesting that host immune vulnerability is key to infection. While antifungal drugs such as triazoles and terbinafine demonstrate low inhibitory concentrations in vitro, combination therapy in mouse models reduces fungal burden but does not completely clear the infection, indicating the necessity for prolonged treatment in immunocompromised hosts. Future exploration may focus on immune restoration and hyperthermia, which may complement antifungal therapy and improve outcomes.
Related
- France’s Pesticide Load Index: Decreasing Ecotoxicity, Persistent Human Toxicity, Rising Concern For Environmental Fate
- Phaeohyphomycosis as a rare cause of brain abscess in immunocompetent patients: Report of two cases.
- Coexisting phaeohyphomycosis and tubercular central nervous system infections in an immunocompetent child: A case report
- Congenital hyperinsulinism as part of a multisystem disease caused by a compound heterozygous variant in the YARS1 gene
- A machine learning classifier reveals hidden rare biallelic heterozygous variants in the coding regions of Meniere disease genome
BibTeX
@article{mei2026persistent,
title = {{Persistent cutaneous phaeohyphomycosis caused by Brunneofusispora hyalina in a patient with a heterozygous CARD9 variant: the opportunistic potential of a newly described environmental fungus}},
author = {Huan Mei and Dongmei Li and Danrui Jing and Xincun Wang and Shuwen Deng and Paul Daly and Hailin Zheng and Xiaodong She and Meihua Fu and Weida Liu},
journal = {Frontiers in Fungal Biology},
year = {2026},
month = oct,
doi = {10.3389/ffunb.2026.1938341},
url = {https://doi.org/10.3389/ffunb.2026.1938341},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Persistent cutaneous phaeohyphomycosis caused by Brunneofusispora hyalina in a patient with a heterozygous CARD9 variant: the opportunistic potential of a newly described environmental fungus
AU - Huan Mei
AU - Dongmei Li
AU - Danrui Jing
AU - Xincun Wang
AU - Shuwen Deng
AU - Paul Daly
AU - Hailin Zheng
AU - Xiaodong She
AU - Meihua Fu
AU - Weida Liu
PY - 2026
DA - 2026/10/13
JO - Frontiers in Fungal Biology
DO - 10.3389/ffunb.2026.1938341
UR - https://doi.org/10.3389/ffunb.2026.1938341
AB - Objectives: This report documents the first isolation of rare dematiaceous fungus Brunneofusispora hyalina from a cutaneous lesion in a patient with heterozygous CARD9 variant. The study characterizes this novel pathogen and simulates infection and treatment processes to understand this opportunist and explore therapeutic strategies. Methods: Direct microscopy and histopathology confirmed the fungal infection. By collecting morphological images of the isolate, assessing temperature-dependent growth, performing multi-locus and whole-genome sequencing, and conducting antifungal susceptibility testing, the new pathogen’s virulence and antifungal resistance were comprehensively analyzed. Using CARD9-deficient mice to establish infection models and administer drug treatments. Results: The patient, confirmed by whole-exome sequencing to have a heterozygous CARD9 variant, was diagnosed with phaeohyphomycosis caused by B. hyalina through barcode sequencing. Meanwhile, functional annotation revealed metabolic versatility and enrichment in secondary metabolite pathways, while 395 PHI homologs were identified mainly from plant-pathogenic fungi. The strain exhibited abundant hyphal anastomosis and psychrotolerant growth. Antifungal susceptibility tests using modified agar dilution and broth dilution methods showed low MICs to voriconazole, posaconazole, itraconazole, and terbinafine, with values of 0.5-1 µg/mL, 0.5–2 µg/mL, 1–2 µg/mL, and 0.25–0.5 µg/mL, respectively. However, fluconazole showed a high MIC (128 µg/mL). In contrast, amphotericin B inhibitory concentrations differed substantially between two testing methods, with discrepancies exceeding three twofold dilution titers. In a CARD9 knockout mouse model, B. hyalina caused persistent inflammatory infections without mortality, whereas infection in wild-type mice had self-limiting symptoms. Despite six weeks of combined antifungal therapy, complete eradication of infection was not achieved. Conclusions: B. hyalina is a new opportunistic fungus causing phaeohyphomycosis, particularly in individuals with CARD9 variants. Genomic analysis shows that B. hyalina shares many genes with plant pathogens and lacks specialized human virulence factors, suggesting that host immune vulnerability is key to infection. While antifungal drugs such as triazoles and terbinafine demonstrate low inhibitory concentrations in vitro, combination therapy in mouse models reduces fungal burden but does not completely clear the infection, indicating the necessity for prolonged treatment in immunocompromised hosts. Future exploration may focus on immune restoration and hyperthermia, which may complement antifungal therapy and improve outcomes.
SN - 2673-6128
ER -